ArticleEmerging microbes & infections2025
Deletion of the African swine fever virus E120R gene completely attenuates its virulence by enhancing host innate immunity and impairing virus release.
Article in Emerging microbes & infections, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Hybrid genotype I and II ASFVEmerging microbes & infections · 2026Article
- Deletion of the D345L gene attenuates ASFV and induces protection against homologous and heterologous challenge by enhancing host innate immunity.Emerging microbes & infections · 2026Article
- FAM134B Restricts African Swine Fever Virus Capsid Assembly via Reticulophagy and Its Antiviral Activity is Antagonized by the Viral Virulence-Associated Factor pMGF300-2R.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Construction of an Oral Vaccine Based on Multiple Antigens of African Swine Fever Virus Displayed on the Surface of Bacillus Subtilis Spores and Study of its Immune Effect in Rats.Current microbiology · 2026Article
- RPSA enhances African swine fever virus entry via caveola-mediated endocytic pathway.Journal of virology · 2026Article
- Novel B cell epitopes mapping in pD205R protein of African swine fever virus using monoclonal antibodies.BMC veterinary research · 2026Article
- Preparation and Epitope Identification of Monoclonal Antibodies Against African Swine Fever Virus pE120R.Veterinary sciences · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
African swine fever virus (ASFV) causes a lethal haemorrhagic disease in domestic pigs and poses a major threat to the global swine industry. Currently, no effective commercial vaccines or antiviral drugs are available for ASF control. In this study, we constructed a recombinant E120R gene-deleted virus, ASFV-ΔE120R, based on the highly virulent genotype II strain SY18, to investigate the role of the E120R gene. ASFV-ΔE120R exhibited impaired virion release and formed aberrant tubular structures, rendering viral particles more susceptible to neutralization by convalescent pig sera. ASFV-ΔE120R induced higher levels of transcription of Cytokines, chemokines, and interferon-regulated genes in porcine alveolar macrophages compared with ASFV-WT. In vivo safety evaluation demonstrated that piglets immunized with 5 × 10⁶ TCID₅₀ of ASFV-ΔE120R exhibited no clinical signs or viral nucleic acid in tissues at necropsy on days 4, 7, 10, and 14 post-immunization. Two immunizations at the same dose, 21 days apart, also induced no clinical signs or viral shedding during a 28-day observation. Immunogenicity analysis showed that ASFV-ΔE120R elicited p54-specific antibodies and IFN-γ-secreting PBMC responses. Upon challenge with parental ASFV SY18, two of five pigs (40%) survived, showing elevated antibody levels, IFN-γ-secreting PBMCs, and increased CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.